Trial: 201903210

A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myeloproliferative Neoplasms)


I/II (Cancer Control)

Principal Investigator

Oh, Stephen

Disease Site

Lymphoid Leukemia; Other Hematopoietic

Learn more about this study at: